SWOG S1512: A Phase II Study of PD-1 Blockade with Pembrolizumab In Patients with Locally Advanced and Metastatic Desmoplastic Melanoma
Demographics (1)
- SEX - Biological sex (phv00565366.v1.p1)
General Health (1)
- SURGERY - Whether the subject received surgery or not (phv00565372.v1.p1)
Other (15)
- ANALYTE_TYPE - Analyte type (phv00565375.v1.p1)
- ASSAY - Assay that led to data type (phv00565376.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00565379.v1.p1)
- COHORT - Cohort corresponding to the trial (phv00565370.v1.p1)
- CONSENT - Registered consent groups (Data Use Limitations (DUL)) as determined by submitters' Institutional Review Boards (IRB) or equivalent body. (phv00565365.v1.p1)
- HISTOLOGICAL_TYPE - Cell or tissue type or subtype of sample (phv00565380.v1.p1)
- IS_TUMOR - Tumor status (phv00565377.v1.p1)
- RECIST_RESPONSE - Best overall response by RECIST version 1.1 (phv00565373.v1.p1)
- SAMPLE_ID - Sample ID (phv00565374.v1.p1)
- SAMPLE_ID - Sample ID (phv00565368.v1.p1)
- SUBJECT_ID - Subject ID (phv00565369.v1.p1)
- SUBJECT_ID - Subject ID (phv00565364.v1.p1)
- SUBJECT_ID - Subject ID (phv00565367.v1.p1)
- TIMEPOINT - Timepoint corresponding to sample collection (phv00565378.v1.p1)
- TREATMENT - Treatment received by patient, also name of randomized arm of the trial (phv00565371.v1.p1)